For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage.

FLXN is a biopharma. There are reports of a potential buyout buy SNY.  The stock is jumping as we are writing.  This is suitable only for super aggressive investors as the risk of loss is very high.  Consider accumulating up to 25% of the full core position size in the zone of $21 to $23.55, preferably below $22.61.  In a buyout the target zone is $28 to $30 if no bidding war and $32 to $36 if there is a bidding war.  The stock is trading at $22.80 and moving up rapidly.

Mental stop loss under $18.